IMU Biosciences
PrivateLast Round
Series A
Jun 2, 2026
Total Funding Raised
$113M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
IMU Biosciences operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A round in June 2026.
IMU Biosciences is a biotechnology company that provides an immune discovery platform using systems-level profiling and AI to advance precision medicine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IMU Biosciences Comparables
Compare IMU Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Teiko Bio | 88% | |
| Immunai | 84% | |
| CytoReason | 82% |
For institutional investors. Book with your work email.
IMU Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 2, 2026 | ||||
| Series A | Jan 24, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
IMU Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LifeX Ventures | Series A, Seed |
| LifeX Ventures | Series A |
| British Business Bank | Series A |
| Meltwind Advisory | Series A |
| IQ Capital | Series A |
| Kfund | Series A |
| Molten Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 112% MoM, reaching 5.7K.
- Jul 27, 2026
Monthly visitors increased 43% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 20, 2026
IMU Biosciences and UK Biobank are developing a single-cell immune profiling AI foundational dataset from 80,000 blood samples using Ultima Genomics' UG200 Sequencing Platform and Waters Corporation's BD Rhapsody Single-Cell Platform, with the project beginning in 2026.
- partners_withOct 19, 2026
On Oct 19th '26, IMU Biosciences and UK Biobank partner in New York to generate large-scale multiomic immune profiling data for 80,000 blood samples.
- receives_financingOct 19, 2026
IMU Biosciences recently receives a $2.1M Sovereign AI grant from the United Kingdom government under its Strategic Assets programme to deliver the project in Oct '26.
For institutional investors. Book with your work email.
IMU Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about IMU Biosciences's valuation, stock price, and market status.
Is IMU Biosciences a public or private company?
IMU Biosciences is a private company.
What is the current stock price of IMU Biosciences?
IMU Biosciences is a private company, so its shares have no public market price. Caplight tracks IMU Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IMU Biosciences worth (valuation)?
Valuation information for IMU Biosciences is not publicly available.
Can I buy IMU Biosciences stock?
IMU Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IMU Biosciences's last funding round?
IMU Biosciences's most recent funding round was Series A on June 2, 2026.
Who are the main investors in IMU Biosciences?
Key investors in IMU Biosciences include IQ Capital, Molten Ventures, IQ Capital.
Will IMU Biosciences IPO soon?
No public IPO plans have been announced for IMU Biosciences.
How can I track IMU Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in IMU Biosciences's shares on secondary markets.